
zzso zzso zzso reside among the most promising targeted zzso agents that are potent zzso of growth arrest, zzso and/or zzso cell death of transformed zzso In October 2006, the US Food and Drug Administration approved the first drug of this new class, zzso zzso zzso zzso Several zzso zzso zzso zzso more are in clinical zzso zzso zzso have shown significant activity against a variety of zzso and solid tumors at doses that are well tolerated by patients, both in zzso as well as in combination therapy with other zzso This paper reviews the most recent developments in zzso inhibitor design, particularly in the context of zzso therapy, and other possible pharmaceutical zzso 

